Sonic Healthcare Limited · ASX:SHL
Sonic Healthcare — Citigroup Investment Conference 2004
24 slides from Sonic Healthcare's conference presentation, Mar 11, 2004
Slide 1: Citigroup Investment Conference London
Citigroup Investment Conference London 11 March 2004 Dr Colin Goldschmidt Managing Director/CEO
Slide 2: Sonic Healthcare
Sonic Healthcare ! Medical Diagnostic Services " Pathology " Radiology ! ASX100 Company " Listed in 1987 " Market Cap ~$2 billion " Largest pathology company in Australia and New Zealand ! Growth " Acquisitions " Organic growth ! Margin Expansion " Marginal profit " Synergies of scale and rationalis
Slide 3: Revenue/EBIT Contribution by Division (FY2003)
Sonic Healthcare Revenue/EBIT Contribution by Division (FY2003) Revenue EBIT Radiology Radiology 27% 25% Pathology Pathology 73% 75%
Slide 4: 25 Operating Subsidiaries
25 Operating Subsidiaries 13 Pathology Companies 9 Radiology Companies 1. Douglass Hanly Moir Pathology/ 1. Queensland X-Ray Barratt & Smith Pathology 2. SKG Radiology 2. Sullivan & Nicolaides Pathology 3. Castlereagh Imaging 3. Melbourne Pathology 4. Hunter Imaging Group 4. Diagnostic Medlab 5. Mer
Slide 5: Margin Expansion
Margin Expansion " Revenue growth and marginal profit ! High fixed costs ! Incremental volume at low unit cost ! Acquisitional and organic growth " Synergy capture ! Centralisation ! Benchmarking ! IT ! Purchasing ! Others
Slide 6: Scale Benefits and Marginal Profit in Pathology
Scale Benefits and Marginal Profit in Pathology 10 9 8 7 6 Cost ($) 5 4 3 2 1 1 2 3 4 5 6 7 8 9 10 Manual Tests Volume (Tests) Automated Tests
Slide 7: Margin Expansion through Rationalisation
Margin Expansion through Rationalisation Douglass Hanly Moir Pathology - Sydney Central Path. Han Ha ly M sk o ir e ll Posney Pa th Douglass Laboratories Douglass Hanly Moir Pathology . bs ith ath a m L P L S n tat & AD Ta S tt rra Ba 1987 2004 1,000 patients/day 14,000 patients/day No staff redunda
Slide 8: 2004 Guidance
2004 Guidance 2003 Actuals 2004 Guidance Growth* $M $M % Revenue 974.8 1,020 – 1,035 5.4% EBITA 173.1 185 - 195 9.8% 2004 Guidance # Growth* calculated using mid-point of 2004 guidance # Includes Omnilabs acquisition (loss in first half) # Intangibles amortisation $59-60 million # Assumes no new acq
Slide 9: Sonic Healthcare 10 Year History
Sonic Healthcare 10 Year History Annual Revenue ($M) EBITA ($M) 1,400 250 1035 195.0 1,200 975 200 173.1 1,000 860 146.7 150 800 628 110.6 $M $M 600 100 387 69.4 400 147 174 50 35.9 200 47 58 89 133 18.4 25.4 13.8 4.7 8.0 0 0 2004(F) 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004(F) 1994 199
Slide 10: Half Year Summary
Sonic Half Year Summary (1 July – 31 Dec 2003) ! Excellent first half performance " EBITA up 13.6% " Core Net Profit up 14.1% (net profit up 35%) " Core EPS up 12.4% " EBITA margin 18.3% (up from 17.0%) ! Solid start to second half " January EBITA strong ! Full-year guidance unchanged " Revenue, EBI
Slide 11: Margin Expansion: EBITA Margin H1 vs Full-year
Sonic Margin Expansion EBITA Margin H1 vs Full-year 20.0% 18.8% 19.0% 18.3% 17.8% 18.0% 17.1% 17.0% 17.0% 15.7% H1 16.0% Full Year 15.0% 14.0% 13.0% 12.0% 2002 2003 2004 = Full-year 2004 EBITA margin forecast derived from upper range of Sonic revenue and EBITA guidance
Slide 12: Growth
Sonic Growth ! Earnings growth in H1, 2004 " EBITA growth-------------13.6% " Core NPAT growth--------14.1% " Core EPS growth----------12.4% ! Consistent EPS growth " Organic growth with marginal profit " Local cost management " Sonic-wide integration synergies ! Growth drivers in medical diagnostic
Slide 13: U.K. Pathology
Sonic U.K. Pathology ! Three Transactions since April 2002 " Acquisition of TDL " Acquisition of Omnilabs " Joint venture with NHS ! UK pathology market ~£2 Billion
Slide 14: The Doctors Laboratory (TDL)
The Doctors Laboratory (TDL) ! Sonic acquired TDL in April 2002 ! Largest private pathology company in UK ! Based in London’s “Harley Street” district ! Co-founded by Dr Ray Prudo (Executive Chairman) in 1987 ! David Byrne (CEO) leads strong management team ! Strong revenue / EBIT growth rates, set
Slide 15: Omnilabs Acquisition
Omnilabs Acquisition ! Omnilabs acquisition from MIA completed in July 2003 ! TDL/Omnilabs merger " Successfully completed in late 2003 ! Losses until merger complete " Incorporated into 2004 guidance ! EBIT contribution from Omnilabs post- merger ~£1M p.a. " Commences after relocation to Whitfield
Slide 16: TDL-UCLH Joint Venture
TDL-UCLH Joint Venture ! Major strategic move for Sonic/TDL ! A significant Public Private Partnership in the NHS ! Joint venture agreement for automated pathology " First of its kind in the UK ! JV structured as a cost sharing arrangement " Cost savings from scale, automation, lab design, workflow
Slide 17: Whitfield St Laboratory
Whitfield St Laboratory ! Floor space 3,400 m² in total " Autolab ~700m² " Balance split between TDL and UCLH operations ! Consolidation of 5 existing TDL/Omnilabs sites ! Fitout of Whitfield St facility essentially complete " State-of-the-art facility and equipment ! Significant excess capacity " T
Slide 18: UK/European Strategy
Sonic UK/European Strategy ! To partner with established players in suitable markets ! TDL platform an ideal base for expansion in UK " Private Pathology Market " NHS Market " Omnilabs and UCLH transactions provide evidence of incremental growth opportunities ! European pathology markets " Fragmente
Slide 19: Sonic Healthcare Today
Sonic Healthcare Today ! Large and growing business " ~$1 Billion annual revenue " > 11,000 employed staff " Efficiency and productivity gains continuous ! Excellent pathology and radiology services " >16 million patients serviced in 2003 " >40 million tests performed in 2003 ! Operational managemen
Slide 20: Core Values
Sonic Core Values " Commit to service excellence " Treat each other with respect and honesty " Demonstrate responsibility and accountability " Strive for continuous improvement " Maintain confidentiality
Slide 21: Successful Outcomes…
Sonic Healthcare Successful Outcomes… Happy Staff s Ha er p om py st Sh Cu ar e py ho p ld Ha er Good Values Good Leadership Good Image s
Slide 22: Good To Great
“Good To Great” Financial The Best in Success the World Passion
Slide 23: Future Growth Strategy
Future Growth Strategy ! Australia and New Zealand " Organic growth and marginal profit " Efficiency gains from existing operations " Synergistic “bolt-on” acquisitions ! UK pathology " TDL organic growth and marginal profit " TDL/Omnilabs/UCLH merger benefits " NHS and Private market expansion ! Eu
Slide 24: Thank you
Thank you eae HEALTHCARE
Sonic Healthcare — Citigroup Investment Conference 2004 on 6ix